CoChat

Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity

Open access
Sun, Linlin, Li, Chia-Wei, Chung, Ezra M., Yang, Riyao, Kim, Yong-Soo, Park, Andrew H., Lai, Yun-Ju, Yang, Yi, Wang, Yu-Han, Liu, Jielin, Qiu, Yufan, Khoo, Kay-Hooi, Yao, Jun, Hsu, Jennifer L., Cha, Jong-Ho, Chan, Li-Chuan, Hsu, Jung-Mao, Lee, Heng-Huan, Yoo, Stephen S., Hung, Mien-Chie · 2020 · Cancer Research
Cited by 166

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) immune checkpoints represent a major breakthrough in cancer treatment. PD-1 is an inhibitory receptor expressed on the surface of activated T cells that dampens T-cell receptor (TCR)/CD28 signaling by engaging with its ligand PD-L1 expressed on cancer cells. Despite the clinical success of PD-1 blockade using mAbs, most patients do not respond to the treatment, and the underlying regulatory mechanisms of PD-1 remain incompletely defined. Here we show that PD-1 is extensively N-glycosylated in T cells and the intensities of its specific glycoforms are altered upon TCR activation. Glycosylation was critical for maintaining PD-1 protein stability and cell surface localization. Glycosylation of PD-1, especially at the N58 site, was essential for mediating its interaction with PD-L1. The mAb STM418 specifically targeted glycosylated PD-1, exhibiting higher binding affinity to PD-1 than FDA-approved PD-1 antibodies, potently inhibiting PD-L1/PD-1 binding, and enhancing antitumor immunity. Together, these findings provide novel insights into the functional significance of PD-1 glycosylation and offer a rationale for targeting glycosylated PD-1 as a potential strategy for immunotherapy. Significance: These findings demonstrate that glycosylation of PD-1 is functionally significant and targeting glycosylated PD-1 may serve as a means to improve immunotherapy response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-19-3133

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 166

Metadata

Authors
Sun, L., Li, C.-W., Chung, E. M., Yang, R., Kim, Y.-S., Park, A. H., Lai, Y.-J., Yang, Y., Wang, Y.-H., Liu, J., Qiu, Y., Khoo, K.-H., Yao, J., Hsu, J. L., Cha, J.-H., Chan, L.-C., Hsu, J.-M., Lee, H.-H., Yoo, S. S., & Hung, M.-C.
Venue
Cancer Research
Published
2020-06-01
Volume
80
Issue
11
Pages
2298-2310
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W3012444842
Cited by
166
References
7
FWCI
6.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-3133
The paper
Sun, L., Li, C.-W., Chung, E. M., Yang, R., Kim, Y.-S., Park, A. H., Lai, Y.-J., Yang, Y., Wang, Y.-H., Liu, J., Qiu, Y., Khoo, K.-H., Yao, J., Hsu, J. L., Cha, J.-H., Chan, L.-C., Hsu, J.-M., Lee, H.-H., Yoo, S. S., & Hung, M.-C. (2020). Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-3133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.